Paper32738245
Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis.
Novais FO and 2 others. J Invest Dermatol, 2021. Cited by 37 papers, by iCite.
Cite this record
ConductScience Library. Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis. Papers, record 32738245. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32738245
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Granzyme B Inhibition by Tofacitinib Blocks the Pathology Induced by CD8 T Cells in Cutaneous Leishmaniasis.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiparasitic Agents | Major topic |
| Granzymes | Major topic |
| Leishmaniasis, Cutaneous | Major topic |
| Piperidines | Major topic |
| Pyrimidines | Major topic |
| T-Lymphocytes, Cytotoxic | Major topic |
| Adoptive Transfer | |
| Animals | |
| Biopsy | |
| Disease Models, Animal | |
| Drug Therapy, Combination | |
| Humans | |
| Leishmania braziliensis | |
| Mice | |
| Parasite Load | |
| Severity of Illness Index | |
| Skin | |
| Th1 Cells |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AI150606 | NIAID NIH HHS | United States | R01AI150606 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 33618802 | Identifying a Potential Therapeutic Host Target in Cutaneous Leishmaniasis. | https://conductscience.org/library/papers/33618802 |
Source PubMed
References73
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28169015 | Janus kinase inhibitors in dermatology: A systematic review. | J Am Acad Dermatol | 2017 | https://conductscience.org/library/papers/28169015 | PubMed |
| 2 | 25036052 | Genomic profiling of human Leishmania braziliensis lesions identifies transcriptional modules associated with cutaneous immunopathology. | J Invest Dermatol | 2015 | https://conductscience.org/library/papers/25036052 | PubMed |
| 3 | 8929454 | Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. | Cell Immunol | 1996 | https://conductscience.org/library/papers/8929454 | PubMed |
| 4 | 12032913 | Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. | Clin Infect Dis | 2002 | https://conductscience.org/library/papers/12032913 | PubMed |
| 5 | 30630365 | Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. | Immunotherapy | 2019 | https://conductscience.org/library/papers/30630365 | PubMed |
| 6 | 28004029 | Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib. | JAAD Case Rep | 2016 | https://conductscience.org/library/papers/28004029 | PubMed |
| 7 | 27842401 | Reversal of Alopecia Universalis by Tofacitinib: A Case Report. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/27842401 | PubMed |
| 8 | 31925782 | Compartmentalized cytotoxic immune response leads to distinct pathogenic roles of natural killer and senescent CD8+ T cells in human cutaneous leishmaniasis. | Immunology | 2020 | https://conductscience.org/library/papers/31925782 | PubMed |
| 9 | 19242513 | Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. | J Invest Dermatol | 2009 | https://conductscience.org/library/papers/19242513 | PubMed |
| 10 | 31106368 | Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/31106368 | PubMed |
| 11 | 30038217 | Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax-infected reticulocytes. | Nat Med | 2018 | https://conductscience.org/library/papers/30038217 | PubMed |
| 12 | 26290604 | Lymphocytic Choriomeningitis Virus Expands a Population of NKG2D+CD8+ T Cells That Exacerbates Disease in Mice Coinfected with Leishmania major. | J Immunol | 2015 | https://conductscience.org/library/papers/26290604 | PubMed |
| 13 | 22873531 | Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22873531 | PubMed |
| 14 | 17188506 | Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. | Cytokine | 2006 | https://conductscience.org/library/papers/17188506 | PubMed |
| 15 | 19346378 | Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. | Am J Trop Med Hyg | 2009 | https://conductscience.org/library/papers/19346378 | PubMed |
| 16 | 22873530 | Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22873530 | PubMed |
| 17 | 25129481 | Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. | Nat Med | 2014 | https://conductscience.org/library/papers/25129481 | PubMed |
| 18 | 28214226 | CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. | Immunity | 2017 | https://conductscience.org/library/papers/28214226 | PubMed |
| 19 | 27516546 | Network pharmacology of JAK inhibitors. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27516546 | PubMed |
| 20 | 9708802 | Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. | Am J Pathol | 1998 | https://conductscience.org/library/papers/9708802 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42084739 | JAK/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients. | Inflamm Res | 2026 | https://conductscience.org/library/papers/42084739 | PubMed |
| 42020513 | Lymphocyte-mediated immune responses to Leishmania infection. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42020513 | PubMed |
| 41272797 | Immunomodulatory and regenerative effects of human umbilical cord MSC-EVs in Cutaneous Leishmaniasis. | Stem Cell Res Ther | 2025 | https://conductscience.org/library/papers/41272797 | PubMed |
| 40982482 | Topical AuNPs-Cys-Sm29 gel modulates the course of lesion development in experimental cutaneous leishmaniasis. | PLoS Negl Trop Dis | 2025 | https://conductscience.org/library/papers/40982482 | PubMed |
| 40952132 | Step-by-step: the CD8 T cell journey in leishmaniasis. | mBio | 2025 | https://conductscience.org/library/papers/40952132 | PubMed |
| 40512023 | Oxygen and immunity to Leishmania infection. | Infect Immun | 2025 | https://conductscience.org/library/papers/40512023 | PubMed |
| 40373956 | Hypoxia and IL-15 Cooperate to Induce Perforin Expression by CD8 T Cells and Promote Damage to the Skin in Murine Cutaneous Leishmaniasis. | J Invest Dermatol | 2025 | https://conductscience.org/library/papers/40373956 | PubMed |
| 40287829 | An overview of host immune responses against Leishmania spp. infections. | Hum Mol Genet | 2025 | https://conductscience.org/library/papers/40287829 | PubMed |
| 39587036 | Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application. | Expert Rev Mol Med | 2024 | https://conductscience.org/library/papers/39587036 | PubMed |
| 39460345 | Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis. | Vaccines (Basel) | 2024 | https://conductscience.org/library/papers/39460345 | PubMed |
| 39432677 | CD8 cell-derived granzyme B may be a predictor for coronary artery involvement and MACE in Takayasu arteritis patients. | Clin Exp Immunol | 2025 | https://conductscience.org/library/papers/39432677 | PubMed |
| 39428748 | Senescence-related genes are associated with the immunopathology signature of American tegumentary leishmaniasis lesions and may predict progression to mucosal leishmaniasis. | Clin Exp Immunol | 2025 | https://conductscience.org/library/papers/39428748 | PubMed |
| 38882602 | CXCR6+CD69+ CD8+ T cells in ascites are associated with disease severity in patients with cirrhosis. | JHEP Rep | 2024 | https://conductscience.org/library/papers/38882602 | PubMed |
| 38787268 | Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions. | Pathogens | 2024 | https://conductscience.org/library/papers/38787268 | PubMed |
| 38709823 | CCR5 promotes the migration of pathological CD8+ T cells to the leishmanial lesions. | PLoS Pathog | 2024 | https://conductscience.org/library/papers/38709823 | PubMed |
| 37873253 | CCR5 promotes the migration of CD8+ T cells to the leishmanial lesions. | bioRxiv | 2023 | https://conductscience.org/library/papers/37873253 | PubMed |
| 37603573 | NKG2D promotes CD8 T cell-mediated cytotoxicity and is associated with treatment failure in human cutaneous leishmaniasis. | PLoS Negl Trop Dis | 2023 | https://conductscience.org/library/papers/37603573 | PubMed |
| 36439094 | Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders. | Front Immunol | 2022 | https://conductscience.org/library/papers/36439094 | PubMed |
| 35757700 | Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection. | Front Immunol | 2022 | https://conductscience.org/library/papers/35757700 | PubMed |
| 35456141 | Protection and Pathology in Leishmania braziliensis Infection. | Pathogens | 2022 | https://conductscience.org/library/papers/35456141 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| GZMB | 3002 | PubTator's text mining | https://conductscience.org/library/genes/3002 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL12B | 3593 | PubTator's text mining | https://conductscience.org/library/genes/3593 | NCBI Gene |
| IL15 | 3600 | PubTator's text mining | https://conductscience.org/library/genes/3600 | NCBI Gene |
| IL2RG | 3561 | PubTator's text mining | https://conductscience.org/library/genes/3561 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32738245
GET https://conductscience.org/api/papers/v1/32738245/references?page=2